StockDuty ← Dashboard Sep 03, 2026 06:35 AM ET
CatalystFDA/Bio

ULTRAGENYX DROPS ON PHASE 3 TRIAL FAILURE FOR ANGELMAN SYNDROME DRUG - SEEKINGALPHA

Phase 3 trial failure for Angelman syndrome drug triggers sharp drop.

What changed
Why it matters
Phase 3 trial failure for Angelman syndrome drug triggers sharp drop.
Sources
seekingalpha
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →